News from anthera pharmaceuticals A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Mar 23, 2010, 17:00 ET

Anthera Pharmaceuticals Welcomes Georgina Kilfoil as Senior Vice President of Product Development and Clinical Operations

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation,...

Mar 04, 2010, 16:30 ET

Anthera Pharmaceuticals Completes Initial Public Offering

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation,...

Feb 08, 2010, 07:00 ET

Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors

Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation,...

May 06, 2009, 07:00 ET

Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome

- Favorable results for secondary endpoints support outcomes benefit Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company...

Mar 24, 2009, 07:00 ET

Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that after...

Nov 11, 2008, 07:00 ET

Anthera's Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease

Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced new data on its lead...

Apr 17, 2008, 01:00 ET

Anthera Presents Data on Varespladib at ATVB Meeting

SAN MATEO, Calif., April 17 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing...

Apr 16, 2008, 01:00 ET

DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

SAN MATEO, Calif., April 16 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing...

Feb 07, 2008, 00:00 ET

Data From Anthera's Plasma Trial to be Presented as Late Breaker at American College Of Cardiology Scientific Sessions

SAN MATEO, Calif., Feb. 7 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory...

Feb 05, 2008, 00:00 ET

Anthera Pharmaceuticals Forms Scientific Advisory Board

SAN MATEO, Calif., Feb. 5 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held drug development company, announced today that it has...

Jan 31, 2008, 00:00 ET

Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials

SAN MATEO, Calif., Jan. 31 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. today announced it has entered into manufacturing agreements with...

Jan 15, 2008, 00:00 ET

Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial

SAN MATEO, Calif., Jan. 15 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company, reported preliminary...

Jan 08, 2008, 00:00 ET

Anthera Pharmaceuticals Acquires the Worldwide Rights to a BAFF Inhibitor for the Treatment of Lupus and Other Autoimmune Diseases

SAN MATEO, Calif., Jan. 8 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held drug development company, announced today that it has...

Dec 18, 2007, 00:00 ET

Anthera's A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

SAN MATEO, Calif., Dec. 18 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing...

Dec 06, 2007, 00:00 ET

Anthera Pharmaceuticals Names Christopher P. Lowe Chief Financial Officer

SAN MATEO, Calif., Dec. 6 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory...

Oct 30, 2007, 01:00 ET

Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors

SAN MATEO, Calif., Oct. 30 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing...

Oct 24, 2007, 01:00 ET

Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial

SAN MATEO, Calif., Oct. 24 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company, reported results of a...

Oct 03, 2007, 01:00 ET

Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease

SAN MATEO, Calif., Oct. 3 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing anti-inflammatory...

Jul 02, 2007, 01:00 ET

Anthera Completes Enrollment of "PLASMA" Trial With A-002 and Announces Initiation of New Investigator Study

SAN MATEO, Calif., July 2 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory...

Apr 13, 2007, 01:00 ET

First Patient Enrolled in Phase 2 'PLASMA' Trial With A-002 for Patients With Coronary Atherosclerosis

SAN MATEO, Calif., April 13 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing...